Core Viewpoint - The company, Jianerkang Medical Technology Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or significant omissions [1][2]. Financial Data Summary - The financial statements for the third quarter of 2025 are unaudited, covering the period from the beginning to the end of the quarter [3]. - The report includes major accounting data and financial indicators, although specific figures are not detailed in the provided text [3]. - The company has not recognized any non-recurring gains or losses that are significant, and there are no changes in the classification of recurring and non-recurring items [3][4]. Shareholder Information - The report does not provide details on the total number of shareholders or any changes in the top ten shareholders due to share lending activities [4]. Financial Statements - The consolidated balance sheet, income statement, and cash flow statement for the period from January to September 2025 have been prepared, but all are unaudited [5]. - The net profit from merged entities prior to consolidation remains at zero for both the current and previous periods [5]. Company Governance - The board of directors and senior management have guaranteed the authenticity and completeness of the quarterly report, taking legal responsibility for its content [2][6].

Core Viewpoint - Jianerkang, a company specializing in disposable medical devices and disinfectant hygiene products, is set to be listed on the Shanghai Stock Exchange on November 7, 2024, showcasing its technological and production advantages in the industry [1] Group 1: Business Performance - In Q3 2025, Jianerkang reported revenue of 725 million yuan, ranking 28th out of 50 in the industry, below the industry average of 1.379 billion yuan and the median of 755 million yuan [2] - The company's net profit for the same period was approximately 76.41 million yuan, ranking 24th in the industry, higher than the median of 75.88 million yuan but lower than the average of 183 million yuan [2] Group 2: Financial Ratios - Jianerkang's debt-to-asset ratio was 11.53% in Q3 2025, down from 15.47% in the previous year and below the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for the same period was 24.28%, an increase from 22.88% year-on-year, but still below the industry average of 48.78% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.15% to 17,100, while the average number of circulating A-shares held per shareholder increased by 38.51% to 2,286.59 [5] - The largest circulating shareholder is the Medical Device ETF (159883), which holds 285,100 shares as a new shareholder [5] Group 4: Executive Compensation - The chairman and general manager, Chen Guoping, received a salary of 1.1473 million yuan in 2024, an increase of 15,400 yuan from 2023 [4]

证券代码：603205 证券简称：健尔康 公告编号：2025-031 健尔康医疗科技股份有限公司 关于部分募集资金投资项目重新论证 并暂缓实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健尔康医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日 召开第二届董事会第十五次会议，审议通过了《关于部分募集资金投资项目重新 论证并暂缓实施的议案》，现将相关事项公告如下： 一、募集资金基本情况 根据中国证监会出具的《关于同意健尔康医疗科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2024]808 号），同意公司首次公开发行股票的 注册申请，并经上海证券交易所同意，公司于 2024 年 10 月 25 日首次向社会公 开发行人民币普通股（A 股）股票 3,000 万股，每股发行价格为人民币 14.65 元， 募集资金总额为人民币 439,500,000.00 元，扣除发行、承销及保荐费用人民币 （ 不 含 增 值 税 ） 53,735,616.16 元 后 ， 实 际 募 集 资 金 净 额 ...

会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 03 日（星期一）至 11 月 07 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lp@chinajek.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 证券代码：603205 证券简称：健尔康 公告编号：2025-032 健尔康医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 健尔康医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 10 日（星期一） 09:00-10:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-030 健尔康医疗科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届董事会第十五次 会议于 2025 年 10 月 30 日以现场和通讯相结合的方式在公司会议室召开，会议 通知于 2025 年 10 月 20 日以书面方式送达。本次会议由董事长陈国平先生主持， 应到董事 9 人，实到董事 9 人。本次董事会的召集、召开和表决程序符合《中华 人民共和国公司法》等有关法律、法规及《健尔康医疗科技股份有限公司章程》 的规定。 二、董事会会议审议情况 经全体董事逐项审议，会议表决情况如下： （一）审议通过《关于公司 2025 年第三季度报告的议案》 （二）审议通过《关于部分募集资金投资项目重新论证并暂缓实施的议案》 本议案已经董事会审计委员会全体同意，并同意提交公司董事会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn ...

中信建投证券股份有限公司关于 健尔康医疗科技股份有限公司 部分募集资金投资项目重新论证并暂缓实施的核查意见 中信建投证券股份有限公司(以下简称"中信建投证券"或"保荐机构") 作 为健尔康医疗科技股份有限公司（以下简称"健尔康"或"公司"持续督导工作 的保荐机构,根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规 则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等相关法规和规范性文件的要求,对健尔康本次部分募集资会投资 项目重新论证并暂缓实施的事项进行了核查,并出具核查意见如下: 二、募集资金投资项目情况 一、募集资金基本情况 根据中国证监会出具的《关于同意健尔康医疗科技股份有限公司首次公开发 行股票注册的批复》(证监许可[2024]808 号),同意公司首次公开发行股票的注册 申请,并经上海证券交易所同意,公司于 2024年 10 月 25 日首次向社会公开发行 人民币普通股(A 股)股票 3,000万股,每股发行价格为人民币 14.65 元,募集资 金总额为人民币 439,500,000.00元,扣除发行、承销及保荐费用人民币(不含增 值税)53,73 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥259,174,054.19, representing a decrease of 6.91% compared to the same period last year[4] - The total profit for the quarter was ¥32,127,193.39, down 13.48% year-over-year[4] - The net profit attributable to shareholders was ¥28,262,353.31, reflecting a decline of 13.07% compared to the previous year[4] - The basic earnings per share for the quarter was ¥0.18, a decrease of 35.71% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥26,451,849.83, down 13.73% year-over-year[4] - Total operating revenue for the first three quarters of 2025 was CNY 725,380,100.62, a decrease of 7.36% compared to CNY 782,935,962.88 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 76,409,567.27, down 18.24% from CNY 93,456,112.74 in 2024[17] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY 0.49, compared to CNY 0.80 in the same period of 2024[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,648,349,562.87, an increase of 3.63% from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥1,152,655,856.26, an increase from ¥1,135,151,347.05 at the end of 2024[14] - Total assets amount to ¥1,648,349,562.87, compared to ¥1,590,569,355.28 at the end of 2024[14] - Non-current assets total ¥495,693,706.61, an increase from ¥455,418,008.23 year-over-year[14] - The total liabilities increased to CNY 190,045,784.37 from CNY 170,433,957.25, indicating a growth of 11.06%[15] - Total equity attributable to shareholders rose to CNY 1,458,303,778.50 from CNY 1,420,135,398.03, an increase of 2.68%[15] Cash Flow - The cash flow from operating activities for the year-to-date was ¥110,289,242.62, showing a decrease of 2.09% compared to the previous year[4] - Cash inflow from operating activities totaled CNY 789,040,144.59, a decrease from CNY 872,741,529.71 in the previous year[20] - Cash paid for purchasing goods and services was CNY 483,547,369.83, down from CNY 559,028,673.33 in 2024[20] - The net cash flow from operating activities was $110,289,242.62, a slight decrease from $112,640,151.54 in the previous period[21] - Total cash outflow from operating activities amounted to $678,750,901.97, compared to $760,101,378.17 last year, indicating a reduction of approximately 10.7%[21] - The net cash flow from investing activities was -$81,385,495.06, an improvement from -$178,589,454.79 in the previous period[21] - Cash inflow from investing activities totaled $176,111,969.73, significantly higher than $695,000.00 in the prior year[21] - Cash outflow for investing activities was $257,497,464.79, up from $179,284,454.79, reflecting an increase of approximately 43.6%[21] - Cash flow from financing activities resulted in a net outflow of -$47,535,369.40, compared to -$3,236,500.00 last year[21] - The cash and cash equivalents at the end of the period were $698,495,922.45, a decrease from $157,274,036.10 in the previous year[21] - The total cash and cash equivalents decreased by $21,433,280.90, compared to a decrease of $67,080,769.16 in the previous period[21] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 17,056[11] - The largest shareholder, Chen Guoping, holds 67,743,000 shares, representing 43.43% of total shares[11] Other Information - Non-recurring gains for the quarter totaled ¥1,810,503.48, with a year-to-date total of ¥4,258,760.46[8] - The company reported a decrease in the diluted earnings per share of 38.75% for the year-to-date period[9] - The company has no reported changes in major shareholders due to stock lending activities[12] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - The company will not apply new accounting standards starting from 2025[22]

（编辑 姚尧） 证券日报网讯 10月14日晚间，健尔康发布公告称，公司于2025年8月28日召开第二届董事会第十四次会 议，审议通过了《关于变更公司注册资本、取消监事会并修订及其附件的议案》《关于修订和制定部分 治理制度的议案》，2025年9月16日公司召开2025年第一次临时股东大会审议通过《关于变更公司注册 资本、取消监事会并修订及其附件的议案》《关于修订和制定部分治理制度的议案》。截至本公告披露 日，公司已完成上述工商备案登记手续。 ...

健尔康医疗科技股份有限公司 章 程 $${\bf\Xi}{\bf\Xi}{\bf O}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}$$ | | | 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为, 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以 下简称"《上市规则》"）、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》和其他有关规定，制订本章程。 第二条 健尔康医疗科技股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第六条 公司注册资本为人民币 15,600 万元。 第七条 公司为永久存续的股份有限公司。 第八条 代表公司执行公司事务的董事为公司的法定代表人。公司董事长为 公司执行公司事务的董事。 公司以发起方式设立，由有限责任公司整体变更为股份有限公司，并在常州 市 市 场 监 督 管 理 局 注 册 登 记 ， 取 得 营 业 执 照 ， 统 一 社 会 信 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-029 健尔康医疗科技股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健尔康医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日 召开第二届董事会第十四次会议，审议通过了《关于变更公司注册资本、取消监 事会并修订<公司章程>及其附件的议案》《关于修订和制定部分治理制度的议案》， 2025 年 9 月 16 日公司召开 2025 年第一次临时股东大会审议通过《关于变更公 司注册资本、取消监事会并修订<公司章程>及其附件的议案》《关于修订和制定 部分治理制度的议案》。相关内容详见公司于 2025 年 8 月 29 日及 2025 年 9 月 17 日在上海证券交易所网站（www.sse.com.cn）以及《上海证券报》《中国证 券报》《证券时报》《证券日报》《经济参考网》披露的相关公告。 截至本公告披露日，公司已完成上述工商备案登记手续，变更后的登记信息 如下: 名称:健尔康医疗科技股份有限公司 许可项目: ...